LONG-TERM EFFICACY AND SAFETY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 104-WEEK RESULTS FROM THE FORTIFY STUDY

被引：0
|
作者：
Panaccione, Remo
Rubin, David T.
Loftus, Edward V.
Lim, Allen
Duan, W. Rachel
Neimark, Ezequiel
Song, Alexandra P.
Kalabic, Jasmina
Zambrano, Javier A.
Kligys, Kristina
Liao, Xiaomei
Koetse, Willem
Hisamatsu, Tadakazu
Danese, Silvio
Peyrin-Biroulet, Laurent
D'Haens, Geert
Ferrante, Marc
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1730
引用
收藏
页码：S1098 / S1099
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial
    Chen, Baili
    Gao, Xiang
    Zhong, Jie
    Ren, Jianlin
    Zhu, Xuan
    Liu, Zhanju
    Wu, Kaichun
    Kalabic, Jasmina
    Yu, Zhuqing
    Huang, Bidan
    Kwatra, Nisha
    Doan, Thao
    Robinson, Anne M.
    Chen, Min-Hu
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [22] LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: FINAL RESULTS FROM THE PHASE 2 OPEN-LABEL EXTENSION STUDY
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip J.
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2020, 158 (06) : S1198 - S1198
  • [23] Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study
    Ferrante, M.
    Feagan, B. G.
    Panes, J.
    Baert, F.
    Louis, E.
    Dewit, O.
    Kaser, A.
    Duan, W. R.
    Gustafson, D.
    Liao, X.
    Wallace, K.
    Kalabic, J.
    D'Haens, G. R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S024 - S025
  • [24] Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn's Disease Not in Clinical Response at Week 12: Results From the GALAXI 1 Study
    Panaccione, Remo
    Afzali, Anita
    D'Haens, Geert R.
    Salese, Leonardo
    Terry, Natalie A.
    Sahoo, Aparna
    Frustaci, Mary Ellen
    Yang, Zijiang
    Zittan, Eran
    Danese, Silvio
    Hisamatsu, Tadakazu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S626 - S626
  • [25] Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn's Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
    Peyrin-Biroulet, L.
    Colombel, J. F.
    Louis, E.
    Ferrante, M.
    Motoya, S.
    Panaccione, R.
    Torres, J.
    Ungaro, R. C.
    Kligys, K.
    Kalabic, J.
    Zambrano, J.
    Zhang, Y.
    D'Haens, G. R.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I046 - I048
  • [26] SHORTER DISEASE DURATION IS ASSOCIATED WITH BETTER OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH RISANKIZUMAB: RESULTS FROM THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
    Peyrin-Biroulet, Laurent
    Colombel, Jean Frederic
    Louis, Edouard
    Ferrante, Marc
    Motoya, Satoshi
    Panaccione, Remo
    Torres, Joana
    Ungaro, Ryan C.
    Kligys, Kristina
    Kalabic, Jasmina
    Zambrano, Javier A.
    Zhang, Yafei
    D'Haens, Geert
    GASTROENTEROLOGY, 2022, 162 (07) : S978 - S978
  • [27] ADDITIONAL RISANKIZUMAB TREATMENT IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO DID NOT ACHIEVE CDAI CLINICAL RESPONSE WITH THE INITIAL 12-WEEK INDUCTION TREATMENT: RESULTS FROM THE ADVANCE, MOTIVATE, AND FORTIFY STUDIES
    Dubinsky, Marla C.
    Rubin, David T.
    Rieder, Florian
    Chapman, J. Casey
    Zambrano, Javier A.
    Kligys, Kristina
    Neimark, Ezequiel
    Zhang, Yafei
    Hanauer, Stephen B.
    GASTROENTEROLOGY, 2023, 164 (06) : S1088 - S1088
  • [28] Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study
    Feagan, Brian G.
    Sandborn, William J.
    D'Haens, Geert R.
    Panes, Julian
    Kaser, Arthur
    Ferrante, Marc
    Louis, Edouard
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Kligys, Kristina
    Wallace, Kori
    Liao, Xiaomei
    Lee, Wan-Ju
    Neurath, Markus F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S482 - S482
  • [29] Efficacy and safety of vedolizumab subcutaneous formulation in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study
    Vermeire, S.
    Sandborn, W.
    Danese, S.
    Baert, F.
    Kobayashi, T.
    Loftus, E.
    Bhatia, S.
    Kisfalvi, K.
    Rosario, M.
    Zhang, W.
    D'Haens, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 115 - 115
  • [30] EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM UNISTAR, A PHASE 1 STUDY
    Rosh, Joel R.
    Turner, Dan
    Griffiths, Anne M.
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Padgett, Lakshmi
    Terry, Natalie A.
    O'Brien, Christopher D.
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2020, 158 (06) : S235 - S236
12345